Median PFS per BICR in patients with tumor cell PD‐L1 expression ≥1% treated with nivolumab plus ipilimumab was 4.0 months (95% CI 2.3–4.4) versus 4.4 months (95% CI 2.9–5.8) with chemotherapy (HR 1.04 [95% CI 0.79–1.36]) (Figure 2C). The gene discussed is CD274; the disease is neoplasm.